Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
10-hydroxycamptothecin + PMID28460551-Compound-2
|
DCOBOY6
|
10-hydroxycamptothecin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
10-hydroxycamptothecin + PMID28460551-Compound-2
|
DCFBTFV
|
10-hydroxycamptothecin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
10-hydroxycamptothecin + PMID28460551-Compound-2
|
DCIMLFW
|
10-hydroxycamptothecin
|
Glioma (Cell Line: SF-539)
|
[1] |
|
10-hydroxycamptothecin + PMID28460551-Compound-2
|
DCXHZOY
|
10-hydroxycamptothecin
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
10-hydroxycamptothecin + PMID28460551-Compound-2
|
DCIEEUC
|
10-hydroxycamptothecin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
ABIRATERONE + PMID28460551-Compound-2
|
DCW2YZA
|
ABIRATERONE
|
Glioma (Cell Line: SF-268)
|
[1] |
|
ABIRATERONE + PMID28460551-Compound-2
|
DCGA9HM
|
ABIRATERONE
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
ABIRATERONE + PMID28460551-Compound-2
|
DCQ3A37
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
ABIRATERONE + PMID28460551-Compound-2
|
DCM0ZNH
|
ABIRATERONE
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
ABIRATERONE + PMID28460551-Compound-2
|
DCVNKHB
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
ABIRATERONE + PMID28460551-Compound-2
|
DCUTYUL
|
ABIRATERONE
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
ABIRATERONE + PMID28460551-Compound-2
|
DCCXXWW
|
ABIRATERONE
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
ABIRATERONE + PMID28460551-Compound-2
|
DCUDBXQ
|
ABIRATERONE
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Acamprosate + PMID28460551-Compound-2
|
DCD7PMK
|
Acamprosate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Acetohexamide + PMID28460551-Compound-2
|
DCONFFH
|
Acetohexamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Allopurinol + PMID28460551-Compound-2
|
DC4CKYS
|
Allopurinol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Alvespimycin hydrochloride + PMID28460551-Compound-2
|
DCYFT79
|
Alvespimycin hydrochloride
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DCRFEZ2
|
Amonafide
|
Adenocarcinoma (Cell Line: DU-145)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DCSOMRN
|
Amonafide
|
Adenocarcinoma (Cell Line: A549)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DC7M7WY
|
Amonafide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DC47UC4
|
Amonafide
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DC9BEOH
|
Amonafide
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DCPNUF8
|
Amonafide
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DC7WTSX
|
Amonafide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DCXWR0D
|
Amonafide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DC63AKQ
|
Amonafide
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DCR1K8Q
|
Amonafide
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DC7YWWR
|
Amonafide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DCJRNSO
|
Amonafide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DCI1HPB
|
Amonafide
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DC5Z1LQ
|
Amonafide
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Amonafide + PMID28460551-Compound-2
|
DCHU064
|
Amonafide
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Amonafide + PMID28460551-Compound-2
|
DC3ATEG
|
Amonafide
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Amonafide + PMID28460551-Compound-2
|
DC37UGO
|
Amonafide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Amonafide + PMID28460551-Compound-2
|
DCFLRLM
|
Amonafide
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Amonafide + PMID28460551-Compound-2
|
DCO4R24
|
Amonafide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Amonafide + PMID28460551-Compound-2
|
DCG7HYI
|
Amonafide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Anamorelin + PMID28460551-Compound-2
|
DC06URR
|
Anamorelin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DCMAH3K
|
Anastrozole
|
Adenocarcinoma (Cell Line: HCT-15)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DCSOZ8Y
|
Anastrozole
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DCNLFYH
|
Anastrozole
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DC9TQKJ
|
Anastrozole
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DC9M9EL
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DCFMR45
|
Anastrozole
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DCGCCYS
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DC4U7ZX
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DCKJW7S
|
Anastrozole
|
Melanoma (Cell Line: MALME-3M)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DC6EVUO
|
Anastrozole
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DC1R7FC
|
Anastrozole
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DCPJTAO
|
Anastrozole
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Anastrozole + PMID28460551-Compound-2
|
DC3TC7I
|
Anastrozole
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Anastrozole + PMID28460551-Compound-2
|
DCCU331
|
Anastrozole
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Anastrozole + PMID28460551-Compound-2
|
DC82ESU
|
Anastrozole
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Arfolitixorin + PMID28460551-Compound-2
|
DCR40PI
|
Arfolitixorin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Arfolitixorin + PMID28460551-Compound-2
|
DC4BDNY
|
Arfolitixorin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Arfolitixorin + PMID28460551-Compound-2
|
DCPHICQ
|
Arfolitixorin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Arfolitixorin + PMID28460551-Compound-2
|
DCVUV71
|
Arfolitixorin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Arfolitixorin + PMID28460551-Compound-2
|
DC1YFUY
|
Arfolitixorin
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Arfolitixorin + PMID28460551-Compound-2
|
DC9KZH2
|
Arfolitixorin
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Arfolitixorin + PMID28460551-Compound-2
|
DCZZO7K
|
Arfolitixorin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Arfolitixorin + PMID28460551-Compound-2
|
DCURU0A
|
Arfolitixorin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Arfolitixorin + PMID28460551-Compound-2
|
DCJJDFZ
|
Arfolitixorin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Armodafinil + PMID28460551-Compound-2
|
DC2D8K2
|
Armodafinil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Asenapine + PMID28460551-Compound-2
|
DCM1XVZ
|
Asenapine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Bafilomycin A1 + PMID28460551-Compound-2
|
DCAD9E1
|
Bafilomycin A1
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[1] |
|
Bepridil + PMID28460551-Compound-2
|
DCJEX0L
|
Bepridil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
BHV-0223 + PMID28460551-Compound-2
|
DCKNRM0
|
BHV-0223
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
BIO-300 + PMID28460551-Compound-2
|
DCL658Z
|
BIO-300
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
BIO-300 + PMID28460551-Compound-2
|
DCZ5TCP
|
BIO-300
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
BIO-300 + PMID28460551-Compound-2
|
DCGBWQX
|
BIO-300
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
BIO-300 + PMID28460551-Compound-2
|
DC3D8JH
|
BIO-300
|
Glioma (Cell Line: SF-268)
|
[1] |
|
BIO-300 + PMID28460551-Compound-2
|
DCT8DLT
|
BIO-300
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
BIO-300 + PMID28460551-Compound-2
|
DCYSBB1
|
BIO-300
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
BIO-300 + PMID28460551-Compound-2
|
DC4PYIO
|
BIO-300
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
BIO-300 + PMID28460551-Compound-2
|
DCGZAU8
|
BIO-300
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
BIO-300 + PMID28460551-Compound-2
|
DC5D23N
|
BIO-300
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DCUT44M
|
BIO-300
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DCPOR2U
|
BIO-300
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DCFVENL
|
BIO-300
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DC092YK
|
BIO-300
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DCKJA31
|
BIO-300
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DCJO46J
|
BIO-300
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DC3NJDN
|
BIO-300
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DCMYYYV
|
BIO-300
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DCMZIJC
|
BIO-300
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
BIO-300 + PMID28460551-Compound-2
|
DCD6IZY
|
BIO-300
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Bleomycin + PMID28460551-Compound-2
|
DC6MTJH
|
Bleomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Bleomycin + PMID28460551-Compound-2
|
DCNHQWL
|
Bleomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Bleomycin + PMID28460551-Compound-2
|
DCUXFBR
|
Bleomycin
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Bleomycin + PMID28460551-Compound-2
|
DCDXQZZ
|
Bleomycin
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Bleomycin + PMID28460551-Compound-2
|
DC8NKNR
|
Bleomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Bleomycin + PMID28460551-Compound-2
|
DCDJ9YD
|
Bleomycin
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Bleomycin + PMID28460551-Compound-2
|
DCJ1737
|
Bleomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Bleomycin + PMID28460551-Compound-2
|
DC1L2HG
|
Bleomycin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Bleomycin + PMID28460551-Compound-2
|
DCHFSN1
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Bleomycin + PMID28460551-Compound-2
|
DC729RR
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Bleomycin + PMID28460551-Compound-2
|
DCDWW8I
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Bleomycin + PMID28460551-Compound-2
|
DC6ELWR
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Bleomycin + PMID28460551-Compound-2
|
DCHWSQU
|
Bleomycin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
BMS-754807 + PMID28460551-Compound-2
|
DC4D1ND
|
BMS-754807
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[1] |
|
Bortezomib + PMID28460551-Compound-2
|
DCZMU2D
|
Bortezomib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
BRL-15572 + PMID28460551-Compound-2
|
DCPM99O
|
BRL-15572
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Bumetanide + PMID28460551-Compound-2
|
DCZC5RM
|
Bumetanide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Busulfan + PMID28460551-Compound-2
|
DCCWFIW
|
Busulfan
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DC02HGE
|
Cabazitaxel
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DC1DNH4
|
Cabazitaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DCUZN79
|
Cabazitaxel
|
Glioma (Cell Line: SF-295)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DCXACSQ
|
Cabazitaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DC31BUH
|
Cabazitaxel
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DCHCC3J
|
Cabazitaxel
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DCK5B70
|
Cabazitaxel
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DCC609W
|
Cabazitaxel
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DCQUGGX
|
Cabazitaxel
|
Melanoma (Cell Line: MALME-3M)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DCF0C0V
|
Cabazitaxel
|
Melanoma (Cell Line: UACC-257)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DC3QM3J
|
Cabazitaxel
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DCKNW2V
|
Cabazitaxel
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DCXAW0T
|
Cabazitaxel
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DCU4EQ8
|
Cabazitaxel
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Cabazitaxel + PMID28460551-Compound-2
|
DCDWWHY
|
Cabazitaxel
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Chlormezanone + PMID28460551-Compound-2
|
DCWF7KV
|
Chlormezanone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Cilastatin + PMID28460551-Compound-2
|
DCCGTCT
|
Cilastatin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Cilostazol + PMID28460551-Compound-2
|
DC66NO1
|
Cilostazol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Cinacalcet + PMID28460551-Compound-2
|
DCLVDYD
|
Cinacalcet
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Clascoterone + PMID28460551-Compound-2
|
DCDHI23
|
Clascoterone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Clopidogrel + PMID28460551-Compound-2
|
DCVS9N0
|
Clopidogrel
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Crizotinib + PMID28460551-Compound-2
|
DC5SUC0
|
Crizotinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Crizotinib + PMID28460551-Compound-2
|
DCKXCLC
|
Crizotinib
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Crizotinib + PMID28460551-Compound-2
|
DCBX6QN
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Crizotinib + PMID28460551-Compound-2
|
DCR9982
|
Crizotinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[1] |
|
Crizotinib + PMID28460551-Compound-2
|
DCARIRI
|
Crizotinib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[1] |
|
Crizotinib + PMID28460551-Compound-2
|
DCIFMLV
|
Crizotinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[1] |
|
Crizotinib + PMID28460551-Compound-2
|
DCK6AHJ
|
Crizotinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[1] |
|
Crizotinib + PMID28460551-Compound-2
|
DCD4CK5
|
Crizotinib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Crizotinib + PMID28460551-Compound-2
|
DCUWTQM
|
Crizotinib
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Cytarabine + PMID28460551-Compound-2
|
DC8XIYX
|
Cytarabine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Dacarbazine + PMID28460551-Compound-2
|
DCTI1FK
|
Dacarbazine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[1] |
|
Dacarbazine + PMID28460551-Compound-2
|
DCJNJOL
|
Dacarbazine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Dacarbazine + PMID28460551-Compound-2
|
DCK89U5
|
Dacarbazine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Dacarbazine + PMID28460551-Compound-2
|
DCIGA1J
|
Dacarbazine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Dacarbazine + PMID28460551-Compound-2
|
DC7GF4K
|
Dacarbazine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Dacarbazine + PMID28460551-Compound-2
|
DCVXDCM
|
Dacarbazine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[1] |
|
Dacarbazine + PMID28460551-Compound-2
|
DCFUB75
|
Dacarbazine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[1] |
|
Dacarbazine + PMID28460551-Compound-2
|
DCZTOYE
|
Dacarbazine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[1] |
|
Dacarbazine + PMID28460551-Compound-2
|
DCLU101
|
Dacarbazine
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Dacarbazine + PMID28460551-Compound-2
|
DCZ1TVK
|
Dacarbazine
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Dacarbazine + PMID28460551-Compound-2
|
DC78RV3
|
Dacarbazine
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Dacarbazine + PMID28460551-Compound-2
|
DC2DBAO
|
Dacarbazine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Dactinomycin + PMID28460551-Compound-2
|
DCQEGSN
|
Dactinomycin
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Dactinomycin + PMID28460551-Compound-2
|
DC21R0R
|
Dactinomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Darunavir + PMID28460551-Compound-2
|
DC0QTVU
|
Darunavir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Desoxycorticosterone pivalate + PMID28460551-Compound-2
|
DC1QJUV
|
Desoxycorticosterone pivalate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Dexamethasone + PMID28460551-Compound-2
|
DC7JN49
|
Dexamethasone
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
Dexamethasone + PMID28460551-Compound-2
|
DCGCX8B
|
Dexamethasone
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Dexamethasone + PMID28460551-Compound-2
|
DC7EDRT
|
Dexamethasone
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Dexmedetomidine + PMID28460551-Compound-2
|
DCHP03K
|
Dexmedetomidine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Dexrazoxane + PMID28460551-Compound-2
|
DCNJP1G
|
Dexrazoxane
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Dexrazoxane + PMID28460551-Compound-2
|
DC2MOEI
|
Dexrazoxane
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Dexrazoxane + PMID28460551-Compound-2
|
DCVBD8W
|
Dexrazoxane
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Dexrazoxane + PMID28460551-Compound-2
|
DC3358W
|
Dexrazoxane
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Dexrazoxane + PMID28460551-Compound-2
|
DCEZ8RC
|
Dexrazoxane
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Dexrazoxane + PMID28460551-Compound-2
|
DCMMBYZ
|
Dexrazoxane
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Dexrazoxane + PMID28460551-Compound-2
|
DCKTS6Z
|
Dexrazoxane
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Dexrazoxane + PMID28460551-Compound-2
|
DCMKFV2
|
Dexrazoxane
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Dexrazoxane + PMID28460551-Compound-2
|
DCTNFW7
|
Dexrazoxane
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Dexrazoxane + PMID28460551-Compound-2
|
DCMH0CE
|
Dexrazoxane
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Dexrazoxane + PMID28460551-Compound-2
|
DCIKNNK
|
Dexrazoxane
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Dextromethorphan + PMID28460551-Compound-2
|
DC0H5KQ
|
Dextromethorphan
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Diethylcarbamazine + PMID28460551-Compound-2
|
DC711LE
|
Diethylcarbamazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Digitoxin + PMID28460551-Compound-2
|
DCUJMDV
|
Digitoxin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Digitoxin + PMID28460551-Compound-2
|
DCV4HGW
|
Digitoxin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Digitoxin + PMID28460551-Compound-2
|
DCIY727
|
Digitoxin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Diphenidol + PMID28460551-Compound-2
|
DCXXNHE
|
Diphenidol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Docetaxel + PMID28460551-Compound-2
|
DCT7IDP
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[1] |
|
Docetaxel + PMID28460551-Compound-2
|
DCCRMMG
|
Docetaxel
|
Adenocarcinoma (Cell Line: HT29)
|
[1] |
|
Docetaxel + PMID28460551-Compound-2
|
DCK1WGW
|
Docetaxel
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[1] |
|
Docetaxel + PMID28460551-Compound-2
|
DC164NC
|
Docetaxel
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Doxapram + PMID28460551-Compound-2
|
DC8RQ2S
|
Doxapram
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCT3SLV
|
Doxorubicin
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCUPEOV
|
Doxorubicin
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCX8PWS
|
Doxorubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCDVMLQ
|
Doxorubicin
|
Adenocarcinoma (Cell Line: NCIH520)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCUR0JR
|
Doxorubicin
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DC8BMLM
|
Doxorubicin
|
Adenocarcinoma (Cell Line: DLD1)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DC99MEM
|
Doxorubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCMCTHN
|
Doxorubicin
|
Adenocarcinoma (Cell Line: HT29)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DC9JU51
|
Doxorubicin
|
Adenocarcinoma (Cell Line: SW-620)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCUKZEY
|
Doxorubicin
|
Amelanotic melanoma (Cell Line: A2058)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DC5OZWT
|
Doxorubicin
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCELW3O
|
Doxorubicin
|
Germ cell tumour (Cell Line: PA1)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DC6K0F3
|
Doxorubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCHPJ58
|
Doxorubicin
|
Malignant melanoma (Cell Line: A375)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCO0LAX
|
Doxorubicin
|
Malignant melanoma (Cell Line: HT144)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCA4N4N
|
Doxorubicin
|
Malignant melanoma (Cell Line: RPMI7951)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCCWVVI
|
Doxorubicin
|
Mesothelioma (Cell Line: MSTO)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCLQYZL
|
Doxorubicin
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCKH544
|
Doxorubicin
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DC5XONO
|
Doxorubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCR6OI1
|
Doxorubicin
|
Prostate carcinoma (Cell Line: VCAP)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCF745L
|
Doxorubicin
|
Prostate carcinoma (Cell Line: LNCAP)
|
[1] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCWMFDR
|
Doxorubicin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCV358Y
|
Doxorubicin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCAK5V5
|
Doxorubicin
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
Doxorubicin + PMID28460551-Compound-2
|
DC1C277
|
Doxorubicin
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCO78OB
|
Doxorubicin
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCKC6T0
|
Doxorubicin
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCQGOS7
|
Doxorubicin
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCIU8DF
|
Doxorubicin
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Doxorubicin + PMID28460551-Compound-2
|
DCPGXUR
|
Doxorubicin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Dronedarone + PMID28460551-Compound-2
|
DC02LZR
|
Dronedarone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Endoxifen + PMID28460551-Compound-2
|
DCIXBTO
|
Endoxifen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Epirubicin + PMID28460551-Compound-2
|
DC9F3UD
|
Epirubicin
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Epirubicin + PMID28460551-Compound-2
|
DCU33Y2
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Epirubicin + PMID28460551-Compound-2
|
DC3BTUQ
|
Epirubicin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Epirubicin + PMID28460551-Compound-2
|
DCC20ZT
|
Epirubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Epirubicin + PMID28460551-Compound-2
|
DCS8X50
|
Epirubicin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Eptifibatide + PMID28460551-Compound-2
|
DCX4TO8
|
Eptifibatide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Estramustine + PMID28460551-Compound-2
|
DC8CRC4
|
Estramustine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Estramustine + PMID28460551-Compound-2
|
DCKPGOR
|
Estramustine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Estramustine + PMID28460551-Compound-2
|
DCTG4KV
|
Estramustine
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
Estramustine + PMID28460551-Compound-2
|
DC7M3ZD
|
Estramustine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Estramustine + PMID28460551-Compound-2
|
DC09MZ4
|
Estramustine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Estramustine + PMID28460551-Compound-2
|
DCUCCCO
|
Estramustine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Estramustine + PMID28460551-Compound-2
|
DCIOK9T
|
Estramustine
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
Estramustine + PMID28460551-Compound-2
|
DCS9Q84
|
Estramustine
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Estramustine + PMID28460551-Compound-2
|
DC67S5H
|
Estramustine
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Estramustine + PMID28460551-Compound-2
|
DCPATI4
|
Estramustine
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
Estramustine + PMID28460551-Compound-2
|
DC52W2O
|
Estramustine
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DCJXN5N
|
Estramustine
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DC7YMCU
|
Estramustine
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DCI2OZQ
|
Estramustine
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DCXSS62
|
Estramustine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DCG8YZN
|
Estramustine
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DCT0BHE
|
Estramustine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DCBH5XZ
|
Estramustine
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DCBFHH5
|
Estramustine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DCYQ2EV
|
Estramustine
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DCUX3UT
|
Estramustine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DC6WGLU
|
Estramustine
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DCVCNJG
|
Estramustine
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DCTVVO6
|
Estramustine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Estramustine + PMID28460551-Compound-2
|
DCDQNUM
|
Estramustine
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
Ethambutol + PMID28460551-Compound-2
|
DCITW2N
|
Ethambutol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Ethinyl estradiol + PMID28460551-Compound-2
|
DC5XGJJ
|
Ethinyl estradiol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
ETHISTERONE + PMID28460551-Compound-2
|
DC38SHE
|
ETHISTERONE
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Etonogestrel + PMID28460551-Compound-2
|
DCOP62W
|
Etonogestrel
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCHP7WM
|
Etoposide
|
Adenocarcinoma (Cell Line: CAOV3)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DC8780N
|
Etoposide
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCOFA9W
|
Etoposide
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCC93ZO
|
Etoposide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCT3CO6
|
Etoposide
|
Adenocarcinoma (Cell Line: NCIH520)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCB0VNF
|
Etoposide
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCP7OIZ
|
Etoposide
|
Adenocarcinoma (Cell Line: DLD1)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCS702W
|
Etoposide
|
Adenocarcinoma (Cell Line: HCT116)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCTS7WU
|
Etoposide
|
Adenocarcinoma (Cell Line: HT29)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCUJHPK
|
Etoposide
|
Adenocarcinoma (Cell Line: SW-620)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCXPD4U
|
Etoposide
|
Amelanotic melanoma (Cell Line: A2058)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCNVHSK
|
Etoposide
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCC42VD
|
Etoposide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCTHLGF
|
Etoposide
|
Malignant melanoma (Cell Line: HT144)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCY96JH
|
Etoposide
|
Malignant melanoma (Cell Line: RPMI7951)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DC2JOGP
|
Etoposide
|
Malignant melanoma (Cell Line: SKMEL30)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DC4YLZB
|
Etoposide
|
Malignant melanoma (Cell Line: UACC62)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCNIL0O
|
Etoposide
|
Mesothelioma (Cell Line: MSTO)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DC0D9HT
|
Etoposide
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCQBNIU
|
Etoposide
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCG9KR8
|
Etoposide
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DC99B7M
|
Etoposide
|
Prostate carcinoma (Cell Line: LNCAP)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DCCFWGO
|
Etoposide
|
Prostate carcinoma (Cell Line: VCAP)
|
[1] |
|
Etoposide + PMID28460551-Compound-2
|
DC3QO8T
|
Etoposide
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Etoposide + PMID28460551-Compound-2
|
DCK6UYC
|
Etoposide
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Etoposide + PMID28460551-Compound-2
|
DCVZIYM
|
Etoposide
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
Etoposide + PMID28460551-Compound-2
|
DC7VKRD
|
Etoposide
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
Etoposide + PMID28460551-Compound-2
|
DC2LV0Z
|
Etoposide
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Etoposide + PMID28460551-Compound-2
|
DCTAFPA
|
Etoposide
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Etoposide + PMID28460551-Compound-2
|
DCL5TV9
|
Etoposide
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Etoposide + PMID28460551-Compound-2
|
DCUPZSV
|
Etoposide
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
Etoposide + PMID28460551-Compound-2
|
DCHU06E
|
Etoposide
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Etoposide + PMID28460551-Compound-2
|
DCU9IJY
|
Etoposide
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Etoposide + PMID28460551-Compound-2
|
DCNWTJ8
|
Etoposide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Etoposide + PMID28460551-Compound-2
|
DCH2VPH
|
Etoposide
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Everolimus + PMID28460551-Compound-2
|
DCJ4HAU
|
Everolimus
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Fenoprofen + PMID28460551-Compound-2
|
DCGUD57
|
Fenoprofen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Flavonoid derivative 1 + PMID28460551-Compound-2
|
DCM70KS
|
Flavonoid derivative 1
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Fludarabine + PMID28460551-Compound-2
|
DCUNFMQ
|
Fludarabine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Fludarabine + PMID28460551-Compound-2
|
DCX18DD
|
Fludarabine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Fludarabine + PMID28460551-Compound-2
|
DCPEFIF
|
Fludarabine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Fludarabine + PMID28460551-Compound-2
|
DCKK2LD
|
Fludarabine
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Fludarabine + PMID28460551-Compound-2
|
DCKIBCX
|
Fludarabine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCNTWNJ
|
Fluorouracil
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCQ5WMI
|
Fluorouracil
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCHJLMV
|
Fluorouracil
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCSNU3J
|
Fluorouracil
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCDHCZI
|
Fluorouracil
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCKI9K3
|
Fluorouracil
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCZDAEL
|
Fluorouracil
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCLP3LF
|
Fluorouracil
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCDF0AX
|
Fluorouracil
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Fluorouracil + PMID28460551-Compound-2
|
DC1JE9J
|
Fluorouracil
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCZRPB3
|
Fluorouracil
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DC5LD0Y
|
Fluorouracil
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCPHJ1U
|
Fluorouracil
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCVF79Y
|
Fluorouracil
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCPDRF8
|
Fluorouracil
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCYNZII
|
Fluorouracil
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DC31Q43
|
Fluorouracil
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCJELQ3
|
Fluorouracil
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCAKOF7
|
Fluorouracil
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCUORU1
|
Fluorouracil
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCEKOL5
|
Fluorouracil
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCU7U7Q
|
Fluorouracil
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCSI37N
|
Fluorouracil
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCVOHI1
|
Fluorouracil
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCFD7VJ
|
Fluorouracil
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCL8RC6
|
Fluorouracil
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCD7OX3
|
Fluorouracil
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCJ09HG
|
Fluorouracil
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCZ1J4V
|
Fluorouracil
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
Fluorouracil + PMID28460551-Compound-2
|
DCWAWIT
|
Fluorouracil
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
Fomepizole + PMID28460551-Compound-2
|
DC7M34B
|
Fomepizole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
FORMESTANE + PMID28460551-Compound-2
|
DCCEBQP
|
FORMESTANE
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
FORMESTANE + PMID28460551-Compound-2
|
DC1S2JM
|
FORMESTANE
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
FORMESTANE + PMID28460551-Compound-2
|
DCHFF2K
|
FORMESTANE
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
FORMESTANE + PMID28460551-Compound-2
|
DCS3OV8
|
FORMESTANE
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Gefitinib + PMID28460551-Compound-2
|
DCV32GF
|
Gefitinib
|
Adenocarcinoma (Cell Line: A549)
|
[1] |
|
Gefitinib + PMID28460551-Compound-2
|
DCQ47T2
|
Gefitinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Gefitinib + PMID28460551-Compound-2
|
DCR6ZTM
|
Gefitinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Gefitinib + PMID28460551-Compound-2
|
DCC2Q28
|
Gefitinib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Gefitinib + PMID28460551-Compound-2
|
DCLCECT
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Gefitinib + PMID28460551-Compound-2
|
DCR480O
|
Gefitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[1] |
|
Gefitinib + PMID28460551-Compound-2
|
DCFG3I0
|
Gefitinib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[1] |
|
Gefitinib + PMID28460551-Compound-2
|
DCWZ3QE
|
Gefitinib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[1] |
|
Gefitinib + PMID28460551-Compound-2
|
DCTI5ZC
|
Gefitinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[1] |
|
Gefitinib + PMID28460551-Compound-2
|
DCRFX41
|
Gefitinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Gefitinib + PMID28460551-Compound-2
|
DC0H8B2
|
Gefitinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[1] |
|
Gefitinib + PMID28460551-Compound-2
|
DC4S898
|
Gefitinib
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Ginsenoside Rb1 + PMID28460551-Compound-2
|
DCP0IZK
|
Ginsenoside Rb1
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
GS4071 + PMID28460551-Compound-2
|
DCKVLG2
|
GS4071
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Hydralazine + PMID28460551-Compound-2
|
DC0ND1V
|
Hydralazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Hyodeoxycholic acid + PMID28460551-Compound-2
|
DCTE6UW
|
Hyodeoxycholic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Imatinib + PMID28460551-Compound-2
|
DCPV0ZY
|
Imatinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DCH0362
|
Indazole derivative 5
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DCB4GB6
|
Indazole derivative 5
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DCPHEAQ
|
Indazole derivative 5
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DCUMIKE
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DCL4ET4
|
Indazole derivative 5
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DCE5MTT
|
Indazole derivative 5
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DC7YJ8R
|
Indazole derivative 5
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Isosorbide dinitrate + PMID28460551-Compound-2
|
DCCDUHB
|
Isosorbide dinitrate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
JNK-IN-8 + PMID28460551-Compound-2
|
DCFR93L
|
JNK-IN-8
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
JNK-IN-8 + PMID28460551-Compound-2
|
DCDOJMS
|
JNK-IN-8
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
JNK-IN-8 + PMID28460551-Compound-2
|
DCYB7AT
|
JNK-IN-8
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
JNK-IN-8 + PMID28460551-Compound-2
|
DCMDOJQ
|
JNK-IN-8
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
JNK-IN-8 + PMID28460551-Compound-2
|
DCICDMD
|
JNK-IN-8
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
JNK-IN-8 + PMID28460551-Compound-2
|
DC01DSA
|
JNK-IN-8
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
JNK-IN-8 + PMID28460551-Compound-2
|
DC1ALVZ
|
JNK-IN-8
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
JZL195 + PMID28460551-Compound-2
|
DC0R4Q7
|
JZL195
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Lenalidomide + PMID28460551-Compound-2
|
DCMS4TH
|
Lenalidomide
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Lenalidomide + PMID28460551-Compound-2
|
DCCPYVP
|
Lenalidomide
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Lenalidomide + PMID28460551-Compound-2
|
DCM89ZI
|
Lenalidomide
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Lenalidomide + PMID28460551-Compound-2
|
DC6ZZ76
|
Lenalidomide
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Levamisole + PMID28460551-Compound-2
|
DCQILBQ
|
Levamisole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
LIAROZOLE + PMID28460551-Compound-2
|
DCY6W76
|
LIAROZOLE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
LIAROZOLE + PMID28460551-Compound-2
|
DC3WYSS
|
LIAROZOLE
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
LIAROZOLE + PMID28460551-Compound-2
|
DCLR8YA
|
LIAROZOLE
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
LIAROZOLE + PMID28460551-Compound-2
|
DC1FUV4
|
LIAROZOLE
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
LIAROZOLE + PMID28460551-Compound-2
|
DC4JHLH
|
LIAROZOLE
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
LIAROZOLE + PMID28460551-Compound-2
|
DC0UB4M
|
LIAROZOLE
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
LIAROZOLE + PMID28460551-Compound-2
|
DC542L0
|
LIAROZOLE
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
LIAROZOLE + PMID28460551-Compound-2
|
DCAID17
|
LIAROZOLE
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
LIAROZOLE + PMID28460551-Compound-2
|
DCT3FEA
|
LIAROZOLE
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
LIAROZOLE + PMID28460551-Compound-2
|
DCA39DE
|
LIAROZOLE
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
LIAROZOLE + PMID28460551-Compound-2
|
DCLT2SY
|
LIAROZOLE
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Linagliptin + PMID28460551-Compound-2
|
DCZ6Y2U
|
Linagliptin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Loperamide + PMID28460551-Compound-2
|
DC5O108
|
Loperamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Maraviroc + PMID28460551-Compound-2
|
DCGZ14H
|
Maraviroc
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Marizomib + PMID28460551-Compound-2
|
DCUCY34
|
Marizomib
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[1] |
|
Mechlorethamine + PMID28460551-Compound-2
|
DCAXYS0
|
Mechlorethamine
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Mechlorethamine + PMID28460551-Compound-2
|
DCXCBG0
|
Mechlorethamine
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Metaxalone + PMID28460551-Compound-2
|
DC9QTIY
|
Metaxalone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Metformin + PMID28460551-Compound-2
|
DC8XTED
|
Metformin
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[1] |
|
Metformin + PMID28460551-Compound-2
|
DCDWI3U
|
Metformin
|
Adenocarcinoma (Cell Line: NCIH520)
|
[1] |
|
Metformin + PMID28460551-Compound-2
|
DCJW8DM
|
Metformin
|
Adenocarcinoma (Cell Line: HT29)
|
[1] |
|
Methotrexate + PMID28460551-Compound-2
|
DC1A101
|
Methotrexate
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[1] |
|
Methotrexate + PMID28460551-Compound-2
|
DCLCKJ2
|
Methotrexate
|
Mesothelioma (Cell Line: MSTO)
|
[1] |
|
Methotrexate + PMID28460551-Compound-2
|
DCSD5GL
|
Methotrexate
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[1] |
|
Methotrexate + PMID28460551-Compound-2
|
DCBFJ7U
|
Methotrexate
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
Methotrexate + PMID28460551-Compound-2
|
DCDC13Q
|
Methotrexate
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Methotrexate + PMID28460551-Compound-2
|
DCZLHLS
|
Methotrexate
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Methotrexate + PMID28460551-Compound-2
|
DC2MVM6
|
Methotrexate
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Metyrosine + PMID28460551-Compound-2
|
DC7QBW3
|
Metyrosine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Mitomycin + PMID28460551-Compound-2
|
DCYB5IS
|
Mitomycin
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
Mitomycin + PMID28460551-Compound-2
|
DCQRF0C
|
Mitomycin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Mitomycin + PMID28460551-Compound-2
|
DC6240I
|
Mitomycin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Mitomycin + PMID28460551-Compound-2
|
DCNV46K
|
Mitomycin
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Mitomycin + PMID28460551-Compound-2
|
DC4U0YS
|
Mitomycin
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Mitomycin + PMID28460551-Compound-2
|
DC7O2HK
|
Mitomycin
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Mitomycin + PMID28460551-Compound-2
|
DC6ZF7F
|
Mitomycin
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Mitomycin + PMID28460551-Compound-2
|
DCGR8JL
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Mitomycin + PMID28460551-Compound-2
|
DCE5KXK
|
Mitomycin
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Mitomycin + PMID28460551-Compound-2
|
DC3VZIY
|
Mitomycin
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DC73SW1
|
Mitomycin
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCWP7N4
|
Mitomycin
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCXHPGU
|
Mitomycin
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCZJOQK
|
Mitomycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCNVTXX
|
Mitomycin
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DC1MGNG
|
Mitomycin
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCMVW3Z
|
Mitomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCNKTI3
|
Mitomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DC5YVPM
|
Mitomycin
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DC2154S
|
Mitomycin
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DC7E8OG
|
Mitomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DC8LGAT
|
Mitomycin
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCFMEX6
|
Mitomycin
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DC0PW6Z
|
Mitomycin
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCO7MDT
|
Mitomycin
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCIM5LI
|
Mitomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCUL2KT
|
Mitomycin
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCW3HUB
|
Mitomycin
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCRSCC2
|
Mitomycin
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCDJ1Y9
|
Mitomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCY91BU
|
Mitomycin
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
Mitomycin + PMID28460551-Compound-2
|
DCPBLAJ
|
Mitomycin
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
Mycophenolic acid + PMID28460551-Compound-2
|
DCQMNAS
|
Mycophenolic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Nabilone + PMID28460551-Compound-2
|
DCVFWPN
|
Nabilone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Nitisinone + PMID28460551-Compound-2
|
DCBFRIG
|
Nitisinone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Novobiocin + PMID28460551-Compound-2
|
DCKKTRK
|
Novobiocin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Olmesartan medoxomil + PMID28460551-Compound-2
|
DC4AOHN
|
Olmesartan medoxomil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Oxandrolone + PMID28460551-Compound-2
|
DC41PUV
|
Oxandrolone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Paromomycin + PMID28460551-Compound-2
|
DCJXX44
|
Paromomycin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PD-0325901 + PMID28460551-Compound-2
|
DC9CNJ3
|
PD-0325901
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[1] |
|
Pentamidine + PMID28460551-Compound-2
|
DCIX375
|
Pentamidine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Pentostatin + PMID28460551-Compound-2
|
DCMT3V1
|
Pentostatin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Pepstatin + PMID28460551-Compound-2
|
DCYQVV7
|
Pepstatin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PFK-158 + PMID28460551-Compound-2
|
DCH9RJZ
|
PFK-158
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Picoplatin + PMID28460551-Compound-2
|
DCKGTFE
|
Picoplatin
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Picoplatin + PMID28460551-Compound-2
|
DCE3AOX
|
Picoplatin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Plinabulin + PMID28460551-Compound-2
|
DCSVK99
|
Plinabulin
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[1] |
|
PMID28460551-Compound-2 + Ribavirin-TP
|
DCT70TX
|
Ribavirin-TP
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Lefaxin
|
DCK6UOP
|
Lefaxin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Pentostatin
|
DC4DSMF
|
Pentostatin
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
PMID28460551-Compound-2 + Pentostatin
|
DC618MO
|
Pentostatin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
PMID28460551-Compound-2 + Mebutamate
|
DCEXCRJ
|
Mebutamate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Fulvestrant
|
DCH7X6J
|
Fulvestrant
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
PMID28460551-Compound-2 + Fulvestrant
|
DCTAH28
|
Fulvestrant
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
PMID28460551-Compound-2 + Clindamycin
|
DC7MHKU
|
Clindamycin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Acetazolamide
|
DCHFIOE
|
Acetazolamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Diethylcarbamazine
|
DC8CEBD
|
Diethylcarbamazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCDFPDF
|
PD-0325901
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Lumefantrine
|
DCC628K
|
Lumefantrine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Kanamycin
|
DCYBKN9
|
Kanamycin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DC1Y9WY
|
Ixabepilone
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
PMID28460551-Compound-2 + Dactinomycin
|
DCWNOWF
|
Dactinomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
PMID28460551-Compound-2 + Dactinomycin
|
DCUT6JV
|
Dactinomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
PMID28460551-Compound-2 + Dactinomycin
|
DC16ICE
|
Dactinomycin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Dactinomycin
|
DCF5SPY
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
PMID28460551-Compound-2 + Dactinomycin
|
DC4FM1J
|
Dactinomycin
|
Glioma (Cell Line: SF-295)
|
[1] |
|
PMID28460551-Compound-2 + Dactinomycin
|
DC91NC8
|
Dactinomycin
|
Glioma (Cell Line: SF-268)
|
[1] |
|
PMID28460551-Compound-2 + Lapatinib
|
DC9C9JI
|
Lapatinib
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCOM4T1
|
Lapatinib
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCYNGJ7
|
Lapatinib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
PMID28460551-Compound-2 + Furazolidone
|
DCQQY90
|
Furazolidone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Chlorphenesin
|
DC7E76W
|
Chlorphenesin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + MK-1775
|
DC2LNBX
|
MK-1775
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Miglustat
|
DCBU9MA
|
Miglustat
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Arsenic trioxide
|
DC4JO3B
|
Arsenic trioxide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
PMID28460551-Compound-2 + Arsenic trioxide
|
DC2K2PC
|
Arsenic trioxide
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
PMID28460551-Compound-2 + RTB101
|
DC8KPP0
|
RTB101
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCY4RGE
|
SCH-900776
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Plicamycin
|
DCFLKXE
|
Plicamycin
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
PMID28460551-Compound-2 + Triapine
|
DCY0ADX
|
Triapine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCE0P88
|
Gemcitabine
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Acitretin
|
DCJ2PEZ
|
Acitretin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Tranexamic acid
|
DCBF0ED
|
Tranexamic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCM7O46
|
10-hydroxycamptothecin
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Topetecan
|
DCRUJLA
|
Topetecan
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCDQRMG
|
Pralatrexate
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCMAU46
|
Pralatrexate
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCGN201
|
Pralatrexate
|
Glioma (Cell Line: SF-539)
|
[1] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCTZC7I
|
Pralatrexate
|
Glioma (Cell Line: SF-268)
|
[1] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCEW4B0
|
SNX-2112
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Methylergonovine
|
DC6X7JC
|
Methylergonovine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Palonosetron
|
DC6N0QP
|
Palonosetron
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Terameprocol
|
DCCE4GE
|
Terameprocol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Guanfacine
|
DC1QB52
|
Guanfacine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCH2MW4
|
SCH 727965
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC8OXX1
|
SCH 727965
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
PMID28460551-Compound-2 + Amodiaquine
|
DCZAGC1
|
Amodiaquine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Ursodeoxycholic acid
|
DC8EI2V
|
Ursodeoxycholic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Memantine
|
DCU7KQ4
|
Memantine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Phenprocoumon
|
DCT8OLQ
|
Phenprocoumon
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + LY03004
|
DCAU62D
|
LY03004
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Marizomib
|
DC2XHTR
|
Marizomib
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[1] |
|
PMID28460551-Compound-2 + Aminosalicylic acid
|
DC2WYCW
|
Aminosalicylic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Pazopanib
|
DC61OAT
|
Pazopanib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + MK-5108
|
DCVI3GX
|
MK-5108
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Bendamustine hydrochloride
|
DCT4OB4
|
Bendamustine hydrochloride
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
PMID28460551-Compound-2 + Fluspirilene
|
DC5EYLV
|
Fluspirilene
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + VR-776
|
DCJD0B6
|
VR-776
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Ciprofibrate
|
DC3XOUN
|
Ciprofibrate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Nizatidine
|
DC8748I
|
Nizatidine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Mitomycin
|
DCG2V5U
|
Mitomycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
PMID28460551-Compound-2 + Mitomycin
|
DCXO8RD
|
Mitomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
PMID28460551-Compound-2 + Mitomycin
|
DC24G71
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
PMID28460551-Compound-2 + Mitomycin
|
DCYUD7H
|
Mitomycin
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
PMID28460551-Compound-2 + Mitomycin
|
DC3G62T
|
Mitomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
PMID28460551-Compound-2 + Diphenidol
|
DC8VXAD
|
Diphenidol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Procarbazine
|
DCN9YBD
|
Procarbazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Tolvaptan
|
DCOOVOS
|
Tolvaptan
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Eflornithine
|
DCD5HXF
|
Eflornithine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + PF-02545920
|
DC5ROFJ
|
PF-02545920
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Trifluoperazine
|
DCQXNU0
|
Trifluoperazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Oseltamivir
|
DCNKW7O
|
Oseltamivir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Ibutilide
|
DC1K3VJ
|
Ibutilide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + GINKGOLIDE A
|
DCFUBAR
|
GINKGOLIDE A
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Diazoxide
|
DCF1HEO
|
Diazoxide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + TEM
|
DC1UGM8
|
TEM
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
PMID28460551-Compound-2 + MK-4827
|
DCK35XT
|
MK-4827
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Pargyline
|
DCSFJ79
|
Pargyline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Idarubicin
|
DCG1V7Z
|
Idarubicin
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Idarubicin
|
DCZIN5P
|
Idarubicin
|
Glioblastoma? (Cell Line: T98G)
|
[1] |
|
PMID28460551-Compound-2 + Methocarbamol
|
DCX9GWK
|
Methocarbamol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Probenecid
|
DCKS00M
|
Probenecid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Lomustine
|
DCP4IKN
|
Lomustine
|
Adenocarcinoma (Cell Line: HT29)
|
[1] |
|
PMID28460551-Compound-2 + Lomustine
|
DCLPSEM
|
Lomustine
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Bleomycin
|
DCR7W8B
|
Bleomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
PMID28460551-Compound-2 + Bleomycin
|
DCZ0S4C
|
Bleomycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
PMID28460551-Compound-2 + Bleomycin
|
DC5XC11
|
Bleomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
PMID28460551-Compound-2 + Pramipexole
|
DC4O69F
|
Pramipexole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCZDIFO
|
Bortezomib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
PMID28460551-Compound-2 + Bortezomib
|
DC5CCGF
|
Bortezomib
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCXBVDO
|
Bortezomib
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Mebendazole
|
DCF4JTE
|
Mebendazole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Moricizine
|
DC1I349
|
Moricizine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Olanzapine
|
DCVMLAU
|
Olanzapine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Dopamine
|
DCUBIUT
|
Dopamine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Enalaprilat
|
DCY4JCX
|
Enalaprilat
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole
|
DC4IYNW
|
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCIDRCG
|
Cisplatin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
PMID28460551-Compound-2 + Cisplatin
|
DC372Q5
|
Cisplatin
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCYY36L
|
Cisplatin
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCAYTFG
|
Cisplatin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
PMID28460551-Compound-2 + Cisplatin
|
DC3S6YS
|
Cisplatin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCG2GX4
|
Cisplatin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCTOWIS
|
Cisplatin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
PMID28460551-Compound-2 + Chlorambucil
|
DCKZMUA
|
Chlorambucil
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
PMID28460551-Compound-2 + Chlorambucil
|
DCH1X6Y
|
Chlorambucil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Acarbose
|
DC017SC
|
Acarbose
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Amantadine
|
DCD9MYA
|
Amantadine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCX89NT
|
Sorafenib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + ER819762
|
DCCYEXH
|
ER819762
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
PMID28460551-Compound-2 + ER819762
|
DCGCDDK
|
ER819762
|
Glioma (Cell Line: SF-268)
|
[1] |
|
PMID28460551-Compound-2 + Asenapine
|
DCN5I91
|
Asenapine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Naltrexone
|
DCD2HPA
|
Naltrexone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Quinine
|
DC1V9OJ
|
Quinine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Vinflunine
|
DCBD2I2
|
Vinflunine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
PMID28460551-Compound-2 + Vinflunine
|
DCSJ6K4
|
Vinflunine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
PMID28460551-Compound-2 + Vinflunine
|
DCQ7SRQ
|
Vinflunine
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
PMID28460551-Compound-2 + Vinflunine
|
DC97MWG
|
Vinflunine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
PMID28460551-Compound-2 + Mercaptopurine
|
DCJITA6
|
Mercaptopurine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
PMID28460551-Compound-2 + Mercaptopurine
|
DC0FW2Z
|
Mercaptopurine
|
Glioma (Cell Line: SF-268)
|
[1] |
|
PMID28460551-Compound-2 + Hydralazine
|
DCWXINU
|
Hydralazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Mefloquine
|
DCM5F1W
|
Mefloquine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Pizotyline
|
DC3993A
|
Pizotyline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Lacosamide
|
DCJFI8V
|
Lacosamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Doxorubicin
|
DC4EVUY
|
Doxorubicin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Zileuton
|
DCR36AC
|
Zileuton
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Silver sulfadiazine
|
DCG530C
|
Silver sulfadiazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Testolactone
|
DCABBPS
|
Testolactone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Olmesartan medoxomil
|
DCVDEAR
|
Olmesartan medoxomil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Auranofin
|
DC19W1G
|
Auranofin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + PMID28870136-Compound-43
|
DCPPF7J
|
PMID28870136-Compound-43
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
PMID28460551-Compound-2 + PMID28870136-Compound-43
|
DC06BQF
|
PMID28870136-Compound-43
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DCVU9VI
|
FORMESTANE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
PMID28460551-Compound-2 + Vorinostat
|
DC3TRZ2
|
Vorinostat
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
PMID28460551-Compound-2 + Aminolevulinic Acid Hydrochloride
|
DCRN6DQ
|
Aminolevulinic Acid Hydrochloride
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
PMID28460551-Compound-2 + Cevimeline
|
DC1OKLA
|
Cevimeline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Metaxalone
|
DC813BO
|
Metaxalone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Aciclovir
|
DCLM74N
|
Aciclovir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Enoxacin
|
DCBWQZE
|
Enoxacin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Raltegravir
|
DCU9VUA
|
Raltegravir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Acetohydroxamic Acid
|
DC8H6RP
|
Acetohydroxamic Acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Ibrutinib
|
DCUSTLK
|
Ibrutinib
|
Diffuse large B cell lymphoma (Cell Line: TMD8)
|
[1] |
|
PMID28460551-Compound-2 + GSK2194069
|
DCLHLUJ
|
GSK2194069
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCA3681
|
Dasatinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCDJKMT
|
Dasatinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCVK7WW
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
PMID28460551-Compound-2 + Nitrosoglutathione
|
DCI0CN8
|
Nitrosoglutathione
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Tetracycline
|
DCV09VQ
|
Tetracycline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Etomidate
|
DCKUF8W
|
Etomidate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28460551-Compound-2 + Fulvestrant
|
DCSVZVO
|
Fulvestrant
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCU80JT
|
PD-0325901
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + PD-0325901
|
DC4MUM6
|
PD-0325901
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + PD-0325901
|
DC9O9JD
|
PD-0325901
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
PMID28460551-Compound-2 + PD-0325901
|
DC7PUHK
|
PD-0325901
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
PMID28460551-Compound-2 + PD-0325901
|
DC1HPL6
|
PD-0325901
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCP3PVI
|
PD-0325901
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCQFRDT
|
PD-0325901
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCRJ3EL
|
PD-0325901
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + PD-0325901
|
DC45PX4
|
PD-0325901
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCB7DJV
|
PD-0325901
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCBHNAG
|
PD-0325901
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCFPN01
|
PD-0325901
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DCCVYNW
|
Ixabepilone
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DCL1UOM
|
Ixabepilone
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DCVDW7A
|
Ixabepilone
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DCALFPL
|
Ixabepilone
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCOJV0Z
|
Lapatinib
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + Lapatinib
|
DC7A4MJ
|
Lapatinib
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCHEZJU
|
Lapatinib
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCYZJ1K
|
Lapatinib
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCC10LP
|
Lapatinib
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCNZ2NH
|
Lapatinib
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCTOBP7
|
Lapatinib
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + Lapatinib
|
DC974QV
|
Lapatinib
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCEKR1K
|
Lapatinib
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
PMID28460551-Compound-2 + Lapatinib
|
DC5IAPB
|
Lapatinib
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCQT9XT
|
Lapatinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
PMID28460551-Compound-2 + Lapatinib
|
DC2YJES
|
Lapatinib
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + MK-1775
|
DCBF5N7
|
MK-1775
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + MK-1775
|
DCO4O3W
|
MK-1775
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
PMID28460551-Compound-2 + MK-1775
|
DCWDHM4
|
MK-1775
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + MK-1775
|
DCD19FK
|
MK-1775
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + MK-1775
|
DCPO0RH
|
MK-1775
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + Cyclophosphamide
|
DC8PYMN
|
Cyclophosphamide
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
PMID28460551-Compound-2 + Methotrexate
|
DCOAWB5
|
Methotrexate
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + Arsenic trioxide
|
DC7A5HC
|
Arsenic trioxide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + Arsenic trioxide
|
DCTM1SU
|
Arsenic trioxide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
PMID28460551-Compound-2 + RTB101
|
DC9NBS4
|
RTB101
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + RTB101
|
DCGBRNJ
|
RTB101
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + RTB101
|
DCF4WBW
|
RTB101
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
PMID28460551-Compound-2 + RTB101
|
DCO1LZ2
|
RTB101
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
PMID28460551-Compound-2 + RTB101
|
DC27CDY
|
RTB101
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + RTB101
|
DCXSJP1
|
RTB101
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + RTB101
|
DCHPJ5X
|
RTB101
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + RTB101
|
DCET4HM
|
RTB101
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + RTB101
|
DC83G70
|
RTB101
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
PMID28460551-Compound-2 + RTB101
|
DC87P6H
|
RTB101
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + RTB101
|
DCRE0CW
|
RTB101
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + RTB101
|
DCT0WDH
|
RTB101
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC4UN7X
|
SCH-900776
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCM4HHD
|
SCH-900776
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCRMHVY
|
SCH-900776
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCWZJ86
|
SCH-900776
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC0J1O2
|
SCH-900776
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC7MIHC
|
SCH-900776
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCQVA1G
|
SCH-900776
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCITM4I
|
Gemcitabine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DC6EUC5
|
Gemcitabine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCCYV6C
|
Gemcitabine
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCSR1WA
|
Gemcitabine
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DC2455R
|
Gemcitabine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DC9NTB5
|
10-hydroxycamptothecin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DC8I16C
|
10-hydroxycamptothecin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DC460P9
|
10-hydroxycamptothecin
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCOHWWV
|
10-hydroxycamptothecin
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCWDIJD
|
10-hydroxycamptothecin
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCLOSRF
|
10-hydroxycamptothecin
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCD0CQT
|
10-hydroxycamptothecin
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCEAAH5
|
10-hydroxycamptothecin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCL9ADU
|
10-hydroxycamptothecin
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCQUJ5X
|
Pralatrexate
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DC58606
|
Pralatrexate
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCQ84DL
|
SNX-2112
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCY53EN
|
SNX-2112
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCZQVGB
|
SNX-2112
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCQRTK9
|
SNX-2112
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCDOSII
|
SNX-2112
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + Terameprocol
|
DCA832Q
|
Terameprocol
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC3QFQU
|
SCH 727965
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC4B27N
|
SCH 727965
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCZRF6F
|
SCH 727965
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC8YQ64
|
SCH 727965
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCW5359
|
SCH 727965
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCBOULC
|
SCH 727965
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCXIFSU
|
SCH 727965
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCSW69F
|
Erlotinib
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCBUGM8
|
Erlotinib
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCA3FKC
|
Erlotinib
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
PMID28460551-Compound-2 + Erlotinib
|
DC6VFZ6
|
Erlotinib
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCZ2IWM
|
Erlotinib
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + Erlotinib
|
DC8E2HH
|
Erlotinib
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + Erlotinib
|
DC6TT3A
|
Erlotinib
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCP1SOY
|
Erlotinib
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
PMID28460551-Compound-2 + Erlotinib
|
DC1E4J8
|
Erlotinib
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCFHC3U
|
Erlotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCBE809
|
Erlotinib
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + Ifosfamide
|
DCP8ZW9
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + MK-5108
|
DCJ6PVD
|
MK-5108
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + MK-5108
|
DCLU1ME
|
MK-5108
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + MK-5108
|
DC66SN3
|
MK-5108
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + MK-5108
|
DCB3J1H
|
MK-5108
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + MK-5108
|
DCFYG5U
|
MK-5108
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + MK-5108
|
DCZ4S79
|
MK-5108
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + MK-5108
|
DCFZST1
|
MK-5108
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + Ridaforolimus
|
DCH8ERN
|
Ridaforolimus
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + Ridaforolimus
|
DC3GBHK
|
Ridaforolimus
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + MK-4827
|
DC3V4DR
|
MK-4827
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + MK-4827
|
DCBUZ7L
|
MK-4827
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
PMID28460551-Compound-2 + MK-4827
|
DC2GLOV
|
MK-4827
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
PMID28460551-Compound-2 + MK-4827
|
DCMSKSS
|
MK-4827
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + MK-4827
|
DC0A5TS
|
MK-4827
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + MK-4827
|
DCFZW34
|
MK-4827
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + MK-4827
|
DCZPHBA
|
MK-4827
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + MK-4827
|
DC7F46V
|
MK-4827
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + MK-4827
|
DCP0OGN
|
MK-4827
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + MK-4827
|
DC3W140
|
MK-4827
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + Idarubicin
|
DCKK333
|
Idarubicin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + Lomustine
|
DCZKRAH
|
Lomustine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + Lomustine
|
DCODSK4
|
Lomustine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + Lomustine
|
DCM7GCZ
|
Lomustine
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
PMID28460551-Compound-2 + Lomustine
|
DCLKOEG
|
Lomustine
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + Lomustine
|
DC6SZDS
|
Lomustine
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + Lomustine
|
DCC75ZS
|
Lomustine
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + Bleomycin
|
DCBQ3P9
|
Bleomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCX8LG8
|
Bortezomib
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCNOIUG
|
Bortezomib
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCBZTAI
|
Bortezomib
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + Bortezomib
|
DC6X64P
|
Bortezomib
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCXO5W9
|
Bortezomib
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCLJSFC
|
Bortezomib
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCB1ZS4
|
Bortezomib
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCEOETQ
|
Bortezomib
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCPAZD4
|
Bortezomib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCKJ95R
|
Bortezomib
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + GSK525762
|
DCPK02H
|
GSK525762
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + GSK525762
|
DCA2VQF
|
GSK525762
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + GSK525762
|
DCGZW09
|
GSK525762
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCSVFXU
|
Cisplatin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCAQKDM
|
Cisplatin
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCAEQ9M
|
Cisplatin
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
PMID28460551-Compound-2 + Cisplatin
|
DC1F4TN
|
Cisplatin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCJN4WR
|
Sorafenib
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCE5V11
|
Sorafenib
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + Sorafenib
|
DC1UXEM
|
Sorafenib
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
PMID28460551-Compound-2 + Sorafenib
|
DC1HG27
|
Sorafenib
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCKE4LE
|
Sorafenib
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCDKOU3
|
Sorafenib
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + ER819762
|
DCSVBQG
|
ER819762
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
PMID28460551-Compound-2 + MK-2206
|
DCZ0LFZ
|
MK-2206
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + MK-2206
|
DCU5OG4
|
MK-2206
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + MK-2206
|
DC8KHWW
|
MK-2206
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
PMID28460551-Compound-2 + MK-2206
|
DCKQVB2
|
MK-2206
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + MK-2206
|
DCU9Z3G
|
MK-2206
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + MK-2206
|
DCQIUTI
|
MK-2206
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + MK-2206
|
DCHFMBB
|
MK-2206
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
PMID28460551-Compound-2 + MK-2206
|
DCXGWFZ
|
MK-2206
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
PMID28460551-Compound-2 + MK-2206
|
DC4YVWR
|
MK-2206
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + MK-2206
|
DCONOH9
|
MK-2206
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + MK-2206
|
DCQHK3S
|
MK-2206
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + Vinflunine
|
DCNQA6J
|
Vinflunine
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DCUUBOT
|
FORMESTANE
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
PMID28460551-Compound-2 + Vorinostat
|
DC7TOV4
|
Vorinostat
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCT9K83
|
Vorinostat
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCOFY89
|
Vorinostat
|
Breast carcinoma (Cell Line: ZR751)
|
[2] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCQFOLQ
|
Vorinostat
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCWJ3OH
|
Vorinostat
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + Vorinostat
|
DC4UCNN
|
Vorinostat
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCFTIYM
|
Vorinostat
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCAW2GI
|
Vorinostat
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCQTTOG
|
Vorinostat
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCTIMBB
|
Vorinostat
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCLFV1G
|
Vorinostat
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + Aminolevulinic Acid Hydrochloride
|
DC0Z1Y5
|
Aminolevulinic Acid Hydrochloride
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
PMID28460551-Compound-2 + Aminolevulinic Acid Hydrochloride
|
DCQKV10
|
Aminolevulinic Acid Hydrochloride
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCZRIPZ
|
Dasatinib
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
PMID28460551-Compound-2 + Dasatinib
|
DC3I1JT
|
Dasatinib
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCIOFBP
|
Dasatinib
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCY2NJ2
|
Dasatinib
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCM3Y64
|
Dasatinib
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCP1JK7
|
Dasatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCGP8V9
|
Dasatinib
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
PMID28460551-Compound-2 + Pentostatin
|
DCW4MFV
|
Pentostatin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
PMID28460551-Compound-2 + Fulvestrant
|
DCPE3PC
|
Fulvestrant
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
PMID28460551-Compound-2 + Fulvestrant
|
DC40EAO
|
Fulvestrant
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
PMID28460551-Compound-2 + Fulvestrant
|
DC3JE5B
|
Fulvestrant
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + Fulvestrant
|
DC2AM1R
|
Fulvestrant
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
PMID28460551-Compound-2 + Fulvestrant
|
DC39RQL
|
Fulvestrant
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + Fulvestrant
|
DC87MA5
|
Fulvestrant
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
PMID28460551-Compound-2 + Fulvestrant
|
DCD4C7L
|
Fulvestrant
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
PMID28460551-Compound-2 + Ruxolitinib
|
DCWF791
|
Ruxolitinib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCZ946N
|
PD-0325901
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCJKNKQ
|
PD-0325901
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCHGW9T
|
PD-0325901
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DC2EB35
|
PD-0325901
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DC4QD00
|
PD-0325901
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCV6OLV
|
PD-0325901
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCJZEEU
|
PD-0325901
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCQO0SX
|
PD-0325901
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCSU961
|
PD-0325901
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCEEBYZ
|
PD-0325901
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCXHD8X
|
PD-0325901
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DC6TGWS
|
PD-0325901
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCN852K
|
PD-0325901
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCQNIUT
|
PD-0325901
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCR5TJH
|
PD-0325901
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCMRYBD
|
PD-0325901
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCRUDNF
|
PD-0325901
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCMRECW
|
PD-0325901
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCV04LU
|
PD-0325901
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCE16QG
|
PD-0325901
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCD217R
|
PD-0325901
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCEWLN0
|
PD-0325901
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + PD-0325901
|
DCSVFFU
|
PD-0325901
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DCTZDSQ
|
Ixabepilone
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DC78IDL
|
Ixabepilone
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DCS89N5
|
Ixabepilone
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DCILY0B
|
Ixabepilone
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DCQ6SB3
|
Ixabepilone
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DCXS5HM
|
Ixabepilone
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DC3PKTQ
|
Ixabepilone
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DCOCAUT
|
Ixabepilone
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
PMID28460551-Compound-2 + Ixabepilone
|
DC9VINL
|
Ixabepilone
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
PMID28460551-Compound-2 + Dactinomycin
|
DCMSP5A
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DC48LEP
|
Lapatinib
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DC2WSKL
|
Lapatinib
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DC1RX46
|
Lapatinib
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCTQTDU
|
Lapatinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCYNBL8
|
Lapatinib
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCOLF6Q
|
Lapatinib
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCOCOSS
|
Lapatinib
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCQRX2B
|
Lapatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCCMJUN
|
Lapatinib
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCUGMAD
|
Lapatinib
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DC5LB93
|
Lapatinib
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCCHRV9
|
Lapatinib
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCU6VW2
|
Lapatinib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCZALWS
|
Lapatinib
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCI9GSJ
|
Lapatinib
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCVUCST
|
Lapatinib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCBY00X
|
Lapatinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCVGY0O
|
Lapatinib
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + Lapatinib
|
DCY3VA2
|
Lapatinib
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCJCM39
|
MK-1775
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCCXX9J
|
MK-1775
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCUOYG5
|
MK-1775
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCYFW4R
|
MK-1775
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCYUU2H
|
MK-1775
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCH8KAJ
|
MK-1775
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCVOJXD
|
MK-1775
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCUTYLL
|
MK-1775
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCEET63
|
MK-1775
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DC3ZEIN
|
MK-1775
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCT2GR0
|
MK-1775
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCE14RQ
|
MK-1775
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCPAH12
|
MK-1775
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCZCR8K
|
MK-1775
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCCKWO2
|
MK-1775
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DC7UTW2
|
MK-1775
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + MK-1775
|
DCYXUY0
|
MK-1775
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + Cyclophosphamide
|
DCVO2X9
|
Cyclophosphamide
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
PMID28460551-Compound-2 + Arsenic trioxide
|
DC9X5OP
|
Arsenic trioxide
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DC7H8ZE
|
RTB101
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCY62RB
|
RTB101
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCA0S7H
|
RTB101
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCMNFOH
|
RTB101
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCUNGWO
|
RTB101
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCFO3O6
|
RTB101
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCTNFXU
|
RTB101
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DC1BYEF
|
RTB101
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCODHD0
|
RTB101
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCHKVPS
|
RTB101
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCIF6M4
|
RTB101
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCKNLGD
|
RTB101
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCWBW8S
|
RTB101
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCWHOCA
|
RTB101
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCP0YTE
|
RTB101
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DC7LMRI
|
RTB101
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCPN52Y
|
RTB101
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DC7DLXM
|
RTB101
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCNDF03
|
RTB101
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCR7062
|
RTB101
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCGOPGW
|
RTB101
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCS724X
|
RTB101
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCYZ3TK
|
RTB101
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + RTB101
|
DCVXLTP
|
RTB101
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCQN0PH
|
SCH-900776
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCNKJ52
|
SCH-900776
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCE0GNZ
|
SCH-900776
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCPA4RV
|
SCH-900776
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCS0XKO
|
SCH-900776
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCIZDRR
|
SCH-900776
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCBYLID
|
SCH-900776
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCJZSO1
|
SCH-900776
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCCT50G
|
SCH-900776
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCYJD69
|
SCH-900776
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCMCMVY
|
SCH-900776
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCV2XN1
|
SCH-900776
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC1W2J7
|
SCH-900776
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCISX8I
|
SCH-900776
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC0SUH2
|
SCH-900776
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCS234W
|
SCH-900776
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCCQFJ0
|
SCH-900776
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC176V4
|
SCH-900776
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCFD8U8
|
SCH-900776
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCGRXZ7
|
SCH-900776
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DCO81SW
|
SCH-900776
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC852SR
|
SCH-900776
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + SCH-900776
|
DC2VE9B
|
SCH-900776
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + Plicamycin
|
DC3OCRL
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
PMID28460551-Compound-2 + Triapine
|
DCXKOL1
|
Triapine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCFUT49
|
Gemcitabine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCBW24O
|
Gemcitabine
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCB1L1H
|
Gemcitabine
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DC4REBS
|
Gemcitabine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCHQ4H9
|
Gemcitabine
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DC1F439
|
Gemcitabine
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCGIZTC
|
Gemcitabine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCI38YC
|
Gemcitabine
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCTON42
|
Gemcitabine
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCGW3D1
|
Gemcitabine
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DC4L9J1
|
Gemcitabine
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DC5BU3B
|
Gemcitabine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCTCDG8
|
Gemcitabine
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCGH59X
|
Gemcitabine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCDIW81
|
Gemcitabine
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCHKB0C
|
Gemcitabine
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCLSEFU
|
Gemcitabine
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + Gemcitabine
|
DCAV4LI
|
Gemcitabine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCS6DEY
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DC4NRL0
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCPV3OI
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCF0IWR
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCZ2UJD
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCAUY3D
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DC1ME6K
|
10-hydroxycamptothecin
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCBW055
|
10-hydroxycamptothecin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCR8CWM
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DC72659
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCEK702
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCHFQ77
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DC4AMUG
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DC6QI84
|
10-hydroxycamptothecin
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DC7UYVF
|
10-hydroxycamptothecin
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCAC6GK
|
10-hydroxycamptothecin
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DC1N3C2
|
10-hydroxycamptothecin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCV5L6E
|
10-hydroxycamptothecin
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + 10-hydroxycamptothecin
|
DCZKO2V
|
10-hydroxycamptothecin
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + Topetecan
|
DCF7K84
|
Topetecan
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + Topetecan
|
DCVP7AR
|
Topetecan
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DC64O3I
|
Pralatrexate
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCZO0UT
|
Pralatrexate
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DC7RX4C
|
Pralatrexate
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DC10HXM
|
Pralatrexate
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DC2TLGN
|
Pralatrexate
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCCM0YI
|
Pralatrexate
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCVZO79
|
Pralatrexate
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCHWI4U
|
Pralatrexate
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCFCN7D
|
Pralatrexate
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCZZ6Q6
|
Pralatrexate
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCOUYTQ
|
SNX-2112
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCTIEAR
|
SNX-2112
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCL86IC
|
SNX-2112
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + SNX-2112
|
DC002P8
|
SNX-2112
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCX2MFC
|
SNX-2112
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + SNX-2112
|
DC9EY8M
|
SNX-2112
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCE92B0
|
SNX-2112
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCJE60S
|
SNX-2112
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + SNX-2112
|
DC56HJ7
|
SNX-2112
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + SNX-2112
|
DCA40XM
|
SNX-2112
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + Terameprocol
|
DC6SCLI
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC07T4H
|
SCH 727965
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCL7LAS
|
SCH 727965
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCG7ISF
|
SCH 727965
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC0241Q
|
SCH 727965
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCOM2CA
|
SCH 727965
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC6946P
|
SCH 727965
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCAMXSP
|
SCH 727965
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCHXSGR
|
SCH 727965
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC85SEE
|
SCH 727965
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC38TFX
|
SCH 727965
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC57ZSV
|
SCH 727965
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DC2PVMT
|
Erlotinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCGXVT1
|
Erlotinib
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCDU6XE
|
Erlotinib
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCCBOTR
|
Erlotinib
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DC1SFK4
|
Erlotinib
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCO6MI1
|
Erlotinib
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCTCT8K
|
Erlotinib
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCMLM62
|
Erlotinib
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCQVJCD
|
Erlotinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCEB0PR
|
Erlotinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCSEJJC
|
Erlotinib
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DC2ZD27
|
Erlotinib
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCS4IR4
|
Erlotinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCPH7R8
|
Erlotinib
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCC73Y9
|
Erlotinib
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCQNOYI
|
Erlotinib
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCTKTI1
|
Erlotinib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DC35VQ9
|
Erlotinib
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCGXAW3
|
Erlotinib
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DC03OBE
|
Erlotinib
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCCMFAW
|
Erlotinib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DCU4UVO
|
Erlotinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DC4QS65
|
Erlotinib
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + Erlotinib
|
DC4WF60
|
Erlotinib
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + Ifosfamide
|
DCHOUFX
|
Ifosfamide
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
PMID28460551-Compound-2 + Ifosfamide
|
DC8C60L
|
Ifosfamide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCBM0RO
|
MK-5108
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCY6SDD
|
MK-5108
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCTOOD7
|
MK-5108
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DC8TY1R
|
MK-5108
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DC6SRZY
|
MK-5108
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCOQNFA
|
MK-5108
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCGSBFD
|
MK-5108
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCV3WK5
|
MK-5108
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCLEVTS
|
MK-5108
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCZ1AZF
|
MK-5108
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCINR6T
|
MK-5108
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCB70AW
|
MK-5108
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCMDD82
|
MK-5108
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCD52I9
|
MK-5108
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCWAX3M
|
MK-5108
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + MK-5108
|
DCKA1TH
|
MK-5108
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + Mitomycin
|
DCEXDY8
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
PMID28460551-Compound-2 + Mitomycin
|
DCR08EP
|
Mitomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
PMID28460551-Compound-2 + Mitomycin
|
DCV3EY8
|
Mitomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
PMID28460551-Compound-2 + Mitomycin
|
DC820ZC
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
PMID28460551-Compound-2 + Mitomycin
|
DCQXJSA
|
Mitomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + Ridaforolimus
|
DCNS3HY
|
Ridaforolimus
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + Ridaforolimus
|
DCCNT58
|
Ridaforolimus
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + Ridaforolimus
|
DCUFY41
|
Ridaforolimus
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + Ridaforolimus
|
DCOE9PV
|
Ridaforolimus
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + Ridaforolimus
|
DCIAE4B
|
Ridaforolimus
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + TEM
|
DCWS79G
|
TEM
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCN7ZAD
|
MK-4827
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCA8UOM
|
MK-4827
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCFAU99
|
MK-4827
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCST9D1
|
MK-4827
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCUWRZF
|
MK-4827
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCKJTAU
|
MK-4827
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DC2DMUJ
|
MK-4827
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCJZOZN
|
MK-4827
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCZLHCY
|
MK-4827
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DC062GC
|
MK-4827
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCKOWPP
|
MK-4827
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DC1DZ16
|
MK-4827
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DC3KLLY
|
MK-4827
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DC42EX4
|
MK-4827
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCOLC5B
|
MK-4827
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCZ1JTT
|
MK-4827
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCEFP0M
|
MK-4827
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCV3LX2
|
MK-4827
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DC2QHWU
|
MK-4827
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCAEXVO
|
MK-4827
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DC4OTAT
|
MK-4827
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + MK-4827
|
DCJ35LH
|
MK-4827
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + Idarubicin
|
DCHJAX8
|
Idarubicin
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + Idarubicin
|
DC3LG5Y
|
Idarubicin
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + Idarubicin
|
DCWNWOX
|
Idarubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + Idarubicin
|
DCY57A0
|
Idarubicin
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + Idarubicin
|
DCN21WR
|
Idarubicin
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + Idarubicin
|
DC4FWYZ
|
Idarubicin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + Idarubicin
|
DCWKRN5
|
Idarubicin
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + Idarubicin
|
DCO0S10
|
Idarubicin
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DCG8UMB
|
Lomustine
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DC17M64
|
Lomustine
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DCV8W9G
|
Lomustine
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DCL3ZIC
|
Lomustine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DCENZ49
|
Lomustine
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DC9XZHG
|
Lomustine
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DCI6W22
|
Lomustine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DCM57OR
|
Lomustine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DCSMDQB
|
Lomustine
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DCC7IHM
|
Lomustine
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DC006ZU
|
Lomustine
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DCR8ABU
|
Lomustine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DCIWOTK
|
Lomustine
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + Lomustine
|
DCKEAJB
|
Lomustine
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + Bleomycin
|
DCXTWRV
|
Bleomycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
PMID28460551-Compound-2 + Bleomycin
|
DCEDVB1
|
Bleomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + Bleomycin
|
DC3XF02
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCK8TK8
|
Bortezomib
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCXCH1H
|
Bortezomib
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCAD5FS
|
Bortezomib
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCCHOZ4
|
Bortezomib
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DC9TEN7
|
Bortezomib
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DC9LR0T
|
Bortezomib
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCRCN16
|
Bortezomib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCR9Q2H
|
Bortezomib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCV23T3
|
Bortezomib
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCBR8M2
|
Bortezomib
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCR8FZA
|
Bortezomib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCEHQ9T
|
Bortezomib
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DC7XXQX
|
Bortezomib
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DC1L6RJ
|
Bortezomib
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCHK1ZI
|
Bortezomib
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCOM8ID
|
Bortezomib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DC5WEU6
|
Bortezomib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DC4XSS1
|
Bortezomib
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCKOXR9
|
Bortezomib
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCGV0D7
|
Bortezomib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCOALUY
|
Bortezomib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCRAVYP
|
Bortezomib
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + Bortezomib
|
DCIHV3W
|
Bortezomib
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + GSK525762
|
DCCA785
|
GSK525762
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + GSK525762
|
DC1XD27
|
GSK525762
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + GSK525762
|
DCCCYGD
|
GSK525762
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + Cisplatin
|
DC98IRH
|
Cisplatin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCSW50N
|
Cisplatin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCF5HCZ
|
Cisplatin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCOALNC
|
Cisplatin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCQ2VH8
|
Cisplatin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
PMID28460551-Compound-2 + Cisplatin
|
DC1D022
|
Cisplatin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
PMID28460551-Compound-2 + Cisplatin
|
DCSLOTU
|
Cisplatin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
PMID28460551-Compound-2 + Chlorambucil
|
DC0ZYLA
|
Chlorambucil
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
PMID28460551-Compound-2 + Chlorambucil
|
DCRJXW5
|
Chlorambucil
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + Chlorambucil
|
DCGOUL9
|
Chlorambucil
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
PMID28460551-Compound-2 + Chlorambucil
|
DCY6FXB
|
Chlorambucil
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
PMID28460551-Compound-2 + Chlorambucil
|
DCGXBLZ
|
Chlorambucil
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
PMID28460551-Compound-2 + Chlorambucil
|
DC0UOZW
|
Chlorambucil
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCACYZQ
|
Sorafenib
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCGPFBM
|
Sorafenib
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DC2OJ7D
|
Sorafenib
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCVS5FW
|
Sorafenib
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCCHFLA
|
Sorafenib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCF8DMH
|
Sorafenib
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCVHU8M
|
Sorafenib
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DC4ZBKH
|
Sorafenib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DC911I3
|
Sorafenib
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCD0DD2
|
Sorafenib
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCENLB1
|
Sorafenib
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCXV32M
|
Sorafenib
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DCEH3FL
|
Sorafenib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DC3Q20R
|
Sorafenib
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + Sorafenib
|
DC87UR8
|
Sorafenib
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + ER819762
|
DCC3J90
|
ER819762
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + ER819762
|
DCHW1ZE
|
ER819762
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + ER819762
|
DCIYQVI
|
ER819762
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
PMID28460551-Compound-2 + ER819762
|
DCQ68UX
|
ER819762
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCZZW9S
|
MK-2206
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCF7663
|
MK-2206
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCARI41
|
MK-2206
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCE4TQF
|
MK-2206
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCIWZ4X
|
MK-2206
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCW65F7
|
MK-2206
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DC9WQT3
|
MK-2206
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCY2VA5
|
MK-2206
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DC0PTHN
|
MK-2206
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DC4AV5V
|
MK-2206
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCL48TT
|
MK-2206
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCE4472
|
MK-2206
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCQ6LJ2
|
MK-2206
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCXH2F8
|
MK-2206
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCT6ME8
|
MK-2206
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCRMZZT
|
MK-2206
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCUO2D0
|
MK-2206
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DCP68PR
|
MK-2206
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
PMID28460551-Compound-2 + MK-2206
|
DC3ZDR2
|
MK-2206
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + Pomalidomide
|
DCHUJDB
|
Pomalidomide
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
PMID28460551-Compound-2 + Vinflunine
|
DCZYW69
|
Vinflunine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
PMID28460551-Compound-2 + Vinflunine
|
DCSAGMW
|
Vinflunine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
PMID28460551-Compound-2 + Vinflunine
|
DC0D1H5
|
Vinflunine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
PMID28460551-Compound-2 + Vinflunine
|
DCRRMLZ
|
Vinflunine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
PMID28460551-Compound-2 + Mercaptopurine
|
DCISRN5
|
Mercaptopurine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
PMID28460551-Compound-2 + Mercaptopurine
|
DCJVK5C
|
Mercaptopurine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DCL7PVS
|
FORMESTANE
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DC7BXZ2
|
FORMESTANE
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DCCGCHL
|
FORMESTANE
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DCJZSID
|
FORMESTANE
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DCLJMOU
|
FORMESTANE
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DC3VCEE
|
Vorinostat
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DC3F4IA
|
Vorinostat
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCG6B9T
|
Vorinostat
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCFGHI0
|
Vorinostat
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCBVUQ9
|
Vorinostat
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DC3E8R7
|
Vorinostat
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DC09PJX
|
Vorinostat
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCJZEVI
|
Vorinostat
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCUN9IP
|
Vorinostat
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCHTWZ6
|
Vorinostat
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCLLQEW
|
Vorinostat
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCUH97P
|
Vorinostat
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DC1MLV2
|
Vorinostat
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCAV7GU
|
Vorinostat
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DC6TOK0
|
Vorinostat
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCLJVMU
|
Vorinostat
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCT0G8H
|
Vorinostat
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCG38RJ
|
Vorinostat
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCIS8M7
|
Vorinostat
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
PMID28460551-Compound-2 + Vorinostat
|
DCQHHEE
|
Vorinostat
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
PMID28460551-Compound-2 + Aminolevulinic Acid Hydrochloride
|
DC64I1I
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
PMID28460551-Compound-2 + Aminolevulinic Acid Hydrochloride
|
DCZGO4H
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
PMID28460551-Compound-2 + Aminolevulinic Acid Hydrochloride
|
DC470GH
|
Aminolevulinic Acid Hydrochloride
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
PMID28460551-Compound-2 + Aminolevulinic Acid Hydrochloride
|
DCG9STD
|
Aminolevulinic Acid Hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + Aminolevulinic Acid Hydrochloride
|
DCRQPEM
|
Aminolevulinic Acid Hydrochloride
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
PMID28460551-Compound-2 + Aminolevulinic Acid Hydrochloride
|
DC45DTY
|
Aminolevulinic Acid Hydrochloride
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCVCSZX
|
Dasatinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCOQ8ZV
|
Dasatinib
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCAHMGO
|
Dasatinib
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCJ1IOV
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCWM64F
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCDKI86
|
Dasatinib
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCGMDEW
|
Dasatinib
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DC42CDK
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCWJZ4D
|
Dasatinib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCVBFJF
|
Dasatinib
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DC7AIQV
|
Dasatinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCJBHD8
|
Dasatinib
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DCNLMM8
|
Dasatinib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
PMID28460551-Compound-2 + Dasatinib
|
DC5PRQK
|
Dasatinib
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
Pomalidomide + PMID28460551-Compound-2
|
DC3004Y
|
Pomalidomide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Pramipexole + PMID28460551-Compound-2
|
DC64701
|
Pramipexole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Primidone + PMID28460551-Compound-2
|
DC77J0O
|
Primidone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Pyrazinamide + PMID28460551-Compound-2
|
DCVP3G6
|
Pyrazinamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Raloxifene + PMID28460551-Compound-2
|
DC3GWBQ
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Ramelteon + PMID28460551-Compound-2
|
DC4S14E
|
Ramelteon
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Rifampin + PMID28460551-Compound-2
|
DCGN7V2
|
Rifampin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Romidepsin + PMID28460551-Compound-2
|
DCB4TQG
|
Romidepsin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Romidepsin + PMID28460551-Compound-2
|
DCIBAL0
|
Romidepsin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Romidepsin + PMID28460551-Compound-2
|
DCON7H8
|
Romidepsin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Ruxolitinib + PMID28460551-Compound-2
|
DC4HBSM
|
Ruxolitinib
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Ruxolitinib + PMID28460551-Compound-2
|
DCHEN2Y
|
Ruxolitinib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Ruxolitinib + PMID28460551-Compound-2
|
DC6K0LE
|
Ruxolitinib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Ruxolitinib + PMID28460551-Compound-2
|
DCYA4EE
|
Ruxolitinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Sirolimus + PMID28460551-Compound-2
|
DCR9UN2
|
Sirolimus
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
Sirolimus + PMID28460551-Compound-2
|
DC4PEYH
|
Sirolimus
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Sivelestat + PMID28460551-Compound-2
|
DCDK9V6
|
Sivelestat
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Spironolactone + PMID28460551-Compound-2
|
DCJDODY
|
Spironolactone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
SY-1425 + PMID28460551-Compound-2
|
DCIHNRU
|
SY-1425
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Taxol + PMID28460551-Compound-2
|
DCW0TM4
|
Taxol
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
Taxol + PMID28460551-Compound-2
|
DCSMPA8
|
Taxol
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Taxol + PMID28460551-Compound-2
|
DCDJ3X0
|
Taxol
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Taxol + PMID28460551-Compound-2
|
DC4JH6Y
|
Taxol
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Taxol + PMID28460551-Compound-2
|
DCXR6S9
|
Taxol
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Taxol + PMID28460551-Compound-2
|
DCFDMBU
|
Taxol
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
Taxol + PMID28460551-Compound-2
|
DCHLYER
|
Taxol
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[2] |
|
Taxol + PMID28460551-Compound-2
|
DCOL3P4
|
Taxol
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Taxol + PMID28460551-Compound-2
|
DC69HGD
|
Taxol
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Taxol + PMID28460551-Compound-2
|
DCCS71X
|
Taxol
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Taxol + PMID28460551-Compound-2
|
DC7NET9
|
Taxol
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCFA8VH
|
Taxol
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCZ51LI
|
Taxol
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCDDWM7
|
Taxol
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DC8E89A
|
Taxol
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCQBZ1R
|
Taxol
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCZT409
|
Taxol
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCIWYIJ
|
Taxol
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCOUQ43
|
Taxol
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCAMPXH
|
Taxol
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCUBTG4
|
Taxol
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCPTIN7
|
Taxol
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCUSRY2
|
Taxol
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCVLAIR
|
Taxol
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCGB5BW
|
Taxol
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DC4ONIJ
|
Taxol
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCY28QW
|
Taxol
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCVWL9B
|
Taxol
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCIDRVJ
|
Taxol
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCE8OUP
|
Taxol
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCLQGG9
|
Taxol
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCAU2F9
|
Taxol
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
Taxol + PMID28460551-Compound-2
|
DCEXR1W
|
Taxol
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
Testosterone + PMID28460551-Compound-2
|
DCUD4X7
|
Testosterone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Theophylline + PMID28460551-Compound-2
|
DCT8F1G
|
Theophylline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Thioguanine + PMID28460551-Compound-2
|
DCJHSZV
|
Thioguanine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Thioguanine + PMID28460551-Compound-2
|
DC4ZDZR
|
Thioguanine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Thioguanine + PMID28460551-Compound-2
|
DCS2G4Y
|
Thioguanine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Thioguanine + PMID28460551-Compound-2
|
DCSN017
|
Thioguanine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Thioguanine + PMID28460551-Compound-2
|
DCO9HHO
|
Thioguanine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Thioguanine + PMID28460551-Compound-2
|
DCQ6L6G
|
Thioguanine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Thioguanine + PMID28460551-Compound-2
|
DCP60IR
|
Thioguanine
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Thioguanine + PMID28460551-Compound-2
|
DCWROCZ
|
Thioguanine
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Thioguanine + PMID28460551-Compound-2
|
DC2BAY8
|
Thioguanine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Thioguanine + PMID28460551-Compound-2
|
DCW4E6O
|
Thioguanine
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Thioguanine + PMID28460551-Compound-2
|
DCOK7BT
|
Thioguanine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Thioguanine + PMID28460551-Compound-2
|
DCI46MF
|
Thioguanine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Thioguanine + PMID28460551-Compound-2
|
DC5GMBC
|
Thioguanine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Thioguanine + PMID28460551-Compound-2
|
DCEWF0O
|
Thioguanine
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Thioguanine + PMID28460551-Compound-2
|
DC9OP3Z
|
Thioguanine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Thioguanine + PMID28460551-Compound-2
|
DCSCV8B
|
Thioguanine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Thioguanine + PMID28460551-Compound-2
|
DCP42FB
|
Thioguanine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Thioguanine + PMID28460551-Compound-2
|
DCB02CU
|
Thioguanine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Tolazoline + PMID28460551-Compound-2
|
DC2HETX
|
Tolazoline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Topotecan + PMID28460551-Compound-2
|
DCFKOU7
|
Topotecan
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Topotecan + PMID28460551-Compound-2
|
DCDUA7M
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Topotecan + PMID28460551-Compound-2
|
DCTJT6N
|
Topotecan
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Topotecan + PMID28460551-Compound-2
|
DCRUGXC
|
Topotecan
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Topotecan + PMID28460551-Compound-2
|
DCBZA6T
|
Topotecan
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DC5UB29
|
Topotecan
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCAK7U2
|
Topotecan
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCR3FXW
|
Topotecan
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCP3YEZ
|
Topotecan
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DC8IDF9
|
Topotecan
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCP60ZP
|
Topotecan
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCG4621
|
Topotecan
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DC4SPUR
|
Topotecan
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCS6M66
|
Topotecan
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCRJ8NN
|
Topotecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCRFWGZ
|
Topotecan
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCCW4QX
|
Topotecan
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DC9PUM8
|
Topotecan
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCY9SX3
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCR4S4G
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DC6TPTV
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DC7QPVW
|
Topotecan
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCSI60C
|
Topotecan
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DC2DIRD
|
Topotecan
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCJEDEP
|
Topotecan
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DC2N8ZF
|
Topotecan
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCITTM5
|
Topotecan
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCFFO3D
|
Topotecan
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCB1JOA
|
Topotecan
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DC7X16O
|
Topotecan
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DC2M8Z3
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCNNVRC
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCFQ1GT
|
Topotecan
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCO9I00
|
Topotecan
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DC91P8V
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCXX779
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DC7R11S
|
Topotecan
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
Topotecan + PMID28460551-Compound-2
|
DCEXI22
|
Topotecan
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Triamterene + PMID28460551-Compound-2
|
DCTM63M
|
Triamterene
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Triflupromazine + PMID28460551-Compound-2
|
DCREPAG
|
Triflupromazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Trifluridine + PMID28460551-Compound-2
|
DCLFBO8
|
Trifluridine
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Trifluridine + PMID28460551-Compound-2
|
DCRTG64
|
Trifluridine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Trifluridine + PMID28460551-Compound-2
|
DCA1R0Q
|
Trifluridine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Trifluridine + PMID28460551-Compound-2
|
DCOXTAZ
|
Trifluridine
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Trifluridine + PMID28460551-Compound-2
|
DC3BV00
|
Trifluridine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Trifluridine + PMID28460551-Compound-2
|
DC9JSC2
|
Trifluridine
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Trifluridine + PMID28460551-Compound-2
|
DCQEXR0
|
Trifluridine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Trifluridine + PMID28460551-Compound-2
|
DCODEF4
|
Trifluridine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Trifluridine + PMID28460551-Compound-2
|
DCDG12V
|
Trifluridine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Trifluridine + PMID28460551-Compound-2
|
DCHJ2N5
|
Trifluridine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Trifluridine + PMID28460551-Compound-2
|
DCE320E
|
Trifluridine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Trifluridine + PMID28460551-Compound-2
|
DCPP7OF
|
Trifluridine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Trihexyphenidyl + PMID28460551-Compound-2
|
DC4SAE6
|
Trihexyphenidyl
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Triiodothyronine + PMID28460551-Compound-2
|
DCGH34I
|
Triiodothyronine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Trimethobenzamide + PMID28460551-Compound-2
|
DC9PRU3
|
Trimethobenzamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Tropisetron + PMID28460551-Compound-2
|
DCS2S4P
|
Tropisetron
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Uracil mustard + PMID28460551-Compound-2
|
DCN9XFT
|
Uracil mustard
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Uracil mustard + PMID28460551-Compound-2
|
DCJQ56D
|
Uracil mustard
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Uracil mustard + PMID28460551-Compound-2
|
DCMVI9G
|
Uracil mustard
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Uracil mustard + PMID28460551-Compound-2
|
DCK9SI5
|
Uracil mustard
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Uracil mustard + PMID28460551-Compound-2
|
DC0WEDU
|
Uracil mustard
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Uracil mustard + PMID28460551-Compound-2
|
DC9MY9F
|
Uracil mustard
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Uracil mustard + PMID28460551-Compound-2
|
DCZKZPT
|
Uracil mustard
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Uracil mustard + PMID28460551-Compound-2
|
DCAOGE9
|
Uracil mustard
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Uracil mustard + PMID28460551-Compound-2
|
DCGOE32
|
Uracil mustard
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Valproic Acid + PMID28460551-Compound-2
|
DC1X6M7
|
Valproic Acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Valrubicin + PMID28460551-Compound-2
|
DCL0PD6
|
Valrubicin
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Valrubicin + PMID28460551-Compound-2
|
DC89CII
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
Valrubicin + PMID28460551-Compound-2
|
DC48Y0V
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Valrubicin + PMID28460551-Compound-2
|
DCE6B9E
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Valrubicin + PMID28460551-Compound-2
|
DCKVQQN
|
Valrubicin
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Valrubicin + PMID28460551-Compound-2
|
DCM62E8
|
Valrubicin
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Valrubicin + PMID28460551-Compound-2
|
DCCZXFO
|
Valrubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Valrubicin + PMID28460551-Compound-2
|
DC2VPZ8
|
Valrubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Valrubicin + PMID28460551-Compound-2
|
DCR8Y4W
|
Valrubicin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Valrubicin + PMID28460551-Compound-2
|
DCQFYGI
|
Valrubicin
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Valrubicin + PMID28460551-Compound-2
|
DCWT5M6
|
Valrubicin
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Valrubicin + PMID28460551-Compound-2
|
DCGXQ8F
|
Valrubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Valrubicin + PMID28460551-Compound-2
|
DCM767B
|
Valrubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Valrubicin + PMID28460551-Compound-2
|
DCTUY6E
|
Valrubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DCWC1R9
|
Valrubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DCBXCDR
|
Valrubicin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DCV4XC2
|
Valrubicin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DCERJVY
|
Valrubicin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DC2F89B
|
Valrubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DCR02UW
|
Valrubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DCAXVBH
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DCQOMVD
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DCIWNBO
|
Valrubicin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DC5ELG1
|
Valrubicin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DCBZUSG
|
Valrubicin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DC1HZBM
|
Valrubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Valrubicin + PMID28460551-Compound-2
|
DCZNYL2
|
Valrubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vandetanib + PMID28460551-Compound-2
|
DC0KO67
|
Vandetanib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vandetanib + PMID28460551-Compound-2
|
DCILISJ
|
Vandetanib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vandetanib + PMID28460551-Compound-2
|
DCB4HLS
|
Vandetanib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + PMID28460551-Compound-2
|
DCYHLFC
|
Vemurafenib
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Vemurafenib + PMID28460551-Compound-2
|
DCR41EN
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + PMID28460551-Compound-2
|
DC68BFA
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vinblastine + PMID28460551-Compound-2
|
DCM80XZ
|
Vinblastine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DCSCOSU
|
Vinblastine
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DC3EKY0
|
Vinblastine
|
Adenocarcinoma (Cell Line: NCIH520)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DCPMKSQ
|
Vinblastine
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DCBHRIN
|
Vinblastine
|
Adenocarcinoma (Cell Line: HT29)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DCSO9BD
|
Vinblastine
|
Amelanotic melanoma (Cell Line: A2058)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DCO71P8
|
Vinblastine
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DC6A2PQ
|
Vinblastine
|
Malignant melanoma (Cell Line: HT144)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DCDGKLO
|
Vinblastine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DCAIM7E
|
Vinblastine
|
Malignant melanoma (Cell Line: UACC62)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DC753KN
|
Vinblastine
|
Mesothelioma (Cell Line: MSTO)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DC3Y084
|
Vinblastine
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DCTEYFA
|
Vinblastine
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DCQD42L
|
Vinblastine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DC2PR2R
|
Vinblastine
|
Prostate carcinoma (Cell Line: VCAP)
|
[1] |
|
Vinblastine + PMID28460551-Compound-2
|
DCGOZX7
|
Vinblastine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Vinblastine + PMID28460551-Compound-2
|
DC60FMG
|
Vinblastine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Vinblastine + PMID28460551-Compound-2
|
DC6BNJY
|
Vinblastine
|
Breast carcinoma (Cell Line: KPL1)
|
[2] |
|
Vinblastine + PMID28460551-Compound-2
|
DCQZB9M
|
Vinblastine
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Vinblastine + PMID28460551-Compound-2
|
DC5T16C
|
Vinblastine
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Vinblastine + PMID28460551-Compound-2
|
DCHUWOJ
|
Vinblastine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Vinblastine + PMID28460551-Compound-2
|
DCLVZQS
|
Vinblastine
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Vincristine + PMID28460551-Compound-2
|
DCLUOLM
|
Vincristine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Vincristine + PMID28460551-Compound-2
|
DCH4AQF
|
Vincristine
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[1] |
|
Vincristine + PMID28460551-Compound-2
|
DCS2Y27
|
Vincristine
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Vinflunine + PMID28460551-Compound-2
|
DCQVSAS
|
Vinflunine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Vinflunine + PMID28460551-Compound-2
|
DCSVAID
|
Vinflunine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Vinflunine + PMID28460551-Compound-2
|
DC3TRQM
|
Vinflunine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Vinflunine + PMID28460551-Compound-2
|
DCN3YZN
|
Vinflunine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Vinflunine + PMID28460551-Compound-2
|
DCYV1ZU
|
Vinflunine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCFCKGW
|
Vinorelbine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[2] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCLIF4J
|
Vinorelbine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[2] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCTUFZP
|
Vinorelbine
|
Breast carcinoma (Cell Line: OCUBM)
|
[2] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCACILS
|
Vinorelbine
|
Carcinoma (Cell Line: OV90)
|
[2] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCWPF99
|
Vinorelbine
|
Carcinoma (Cell Line: EFM192B)
|
[2] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCRVPWE
|
Vinorelbine
|
Carcinoma (Cell Line: MDAMB436)
|
[2] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCOPW7Z
|
Vinorelbine
|
Colon carcinoma (Cell Line: RKO)
|
[2] |
|
Vinorelbine + PMID28460551-Compound-2
|
DC7AKC6
|
Vinorelbine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCLG88F
|
Vinorelbine
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[2] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCKCNT7
|
Vinorelbine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCFLDFX
|
Vinorelbine
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DC7X7Q5
|
Vinorelbine
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCJT3GX
|
Vinorelbine
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCYFCJL
|
Vinorelbine
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCW76I7
|
Vinorelbine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCRPI8B
|
Vinorelbine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCQCLA9
|
Vinorelbine
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCV6FDS
|
Vinorelbine
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCRKDCW
|
Vinorelbine
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCDJYOB
|
Vinorelbine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCLZ8LY
|
Vinorelbine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCLDN11
|
Vinorelbine
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCTO214
|
Vinorelbine
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCT4CVM
|
Vinorelbine
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCNUJF6
|
Vinorelbine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCJ6IKD
|
Vinorelbine
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
Vinorelbine + PMID28460551-Compound-2
|
DCY6N5M
|
Vinorelbine
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
Vismodegib + PMID28460551-Compound-2
|
DCGFDIG
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vismodegib + PMID28460551-Compound-2
|
DCABPMJ
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vismodegib + PMID28460551-Compound-2
|
DC3XBT2
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vismodegib + PMID28460551-Compound-2
|
DCH2D6A
|
Vismodegib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vismodegib + PMID28460551-Compound-2
|
DCN698B
|
Vismodegib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
